Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis

ConclusionLD-IL-2 treatment showed promise and was well tolerated in the management of ARDs, as it effectively promoted the proliferation and functional recovery of Tregs.Trial RegistrationRetrospectively registered (CRD42022318916, 21/04/2022).
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research